CIBA-GEIGY SEEKS FOREIGN INVESTORS

10 May 1992

Swiss drugs major Ciba-Geigy will make strenuous efforts to gain more foreign investors as shareholders, according to supervisory council president, Alex Krauer.

Speaking to Swiss media in Basel on issues of mainly domestic concern, Mr Krauer noted that the group's 1991 results had been presented in London in March (Marketletter March 30) in order to widen the shareholder base. He added that Ciba-Geigy had remained relatively unknown, especially to Anglo-Saxon investors.

Mr Krauer explained that there was no upper limit for the proportion of foreign investment in the company. Competition in international capital markets had intensified, and the company had reached its limits on the creation of new capital in Switzerland. Since Ciba-Geigy opened its share capital to foreigners, their share in the company has increased to some 25%, but a proportion of over 50% is quite possible, according to Mr Krauer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight